Clinical Trials Logo

Clinical Trial Summary

Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy


Clinical Trial Description

Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China (Chidamide,a novel histone deacetylase inhibitor). Tirelizumab,has been approved for the failure treatment of platinum-containing chemotherapy with high PD-L1 expression included locally advanced or metastatic Urothelial carcinoma in China(Tirelizumab,BGB-A317 is an investigational humanized IgG4 anti-PD-1 monoclonal antibody ).The aim of this study was to observe the efficacy and safety of Chidamide with Immunotherapy in patients with progression of platinum-based chemotherapy recurrent and metastatic Urothelial carcinoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04562311
Study type Interventional
Source Sun Yat-sen University
Contact Weizhuo Liu, M.D
Phone 86-20-87343868
Email liuzhw@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date October 1, 2020
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT04598724 - Addressing Barriers to Palliative Care Use in Bladder Cancer